468,210 Shares in Kinnate Biopharma Inc. (NASDAQ:KNTE) Acquired by BML Capital Management LLC

BML Capital Management LLC acquired a new position in shares of Kinnate Biopharma Inc. (NASDAQ:KNTE) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 468,210 shares of the company’s stock, valued at approximately $1,110,000. Kinnate Biopharma comprises about 0.8% of BML Capital Management LLC’s investment portfolio, making the stock its 21st largest holding. BML Capital Management LLC owned 0.99% of Kinnate Biopharma as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of KNTE. Connor Clark & Lunn Investment Management Ltd. acquired a new position in Kinnate Biopharma in the 3rd quarter valued at $73,000. Pale Fire Capital SE raised its holdings in Kinnate Biopharma by 196.3% in the 3rd quarter. Pale Fire Capital SE now owns 70,174 shares of the company’s stock valued at $98,000 after acquiring an additional 46,492 shares during the last quarter. Citigroup Inc. raised its holdings in Kinnate Biopharma by 53,138.6% in the 3rd quarter. Citigroup Inc. now owns 420,585 shares of the company’s stock valued at $589,000 after acquiring an additional 419,795 shares during the last quarter. Finally, Acadian Asset Management LLC raised its holdings in Kinnate Biopharma by 71.0% in the 3rd quarter. Acadian Asset Management LLC now owns 736,686 shares of the company’s stock valued at $1,030,000 after acquiring an additional 305,884 shares during the last quarter. 80.89% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. William Blair cut shares of Kinnate Biopharma from an “outperform” rating to a “market perform” rating in a research note on Friday, February 16th. Stifel Nicolaus boosted their price objective on shares of Kinnate Biopharma to $2.59 and gave the company a “hold” rating in a research note on Monday, February 26th. Finally, Wedbush reissued a “neutral” rating and set a $2.00 price objective on shares of Kinnate Biopharma in a research note on Wednesday, January 17th. Five research analysts have rated the stock with a hold rating, Based on data from MarketBeat, Kinnate Biopharma currently has an average rating of “Hold” and a consensus target price of $8.15.

Kinnate Biopharma Stock Down 0.4 %

Shares of KNTE traded down $0.01 during mid-day trading on Wednesday, hitting $2.65. The stock had a trading volume of 2,812,200 shares, compared to its average volume of 418,678. The company has a market cap of $125.13 million, a PE ratio of -0.95 and a beta of 1.38. The company’s fifty day simple moving average is $2.58 and its two-hundred day simple moving average is $2.22. Kinnate Biopharma Inc. has a fifty-two week low of $1.04 and a fifty-two week high of $7.18.

Kinnate Biopharma Profile

Kinnate Biopharma Inc, a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program.